• Agenda At-a-Glance*

    * Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

    Breast Cancer Track

    Hereditary Breast Cancer:
    Genetic Testing and Management of High Risk Women
    Judy E. Garber, MD, MPH

    Management of HER2 Positive and Triple-Negative Breast Cancers
    Eric P. Winer, MD

    Management of ER Positive Breast Cancers
    Harold J. Burstein, MD, PhD

    Panel Discussion
    All Faculty

    Supportive Care Track

    Palliative Care for Cancer Patients:
    Symptom Management and Communication Challenges
    Janet L. Abrahm, MD

    Caring for Cancer Survivors:
    A Comprehensive Approach
    Ann H. Partridge, MD, MPH

    Genitourinary Cancers Track

    Advanced Prostate Cancer:
    The Evolving Landscape
    Philip W. Kantoff, MD

    Bladder and Renal Cancers:
    Preliminary Considerations for Integrating Next Generation Therapeutics
    Robert Dreicer, MD

    Head, Neck and Lung Cancers Track

    Head and Neck and Thyroid Cancers:
    Recent Advances and Current Management Strategies
    Robert I. Haddad, MD

    Lung Cancer:
    Personalized Approaches to Non-Small Cell and Small Cell Lung Cancer
    Bruce E. Johnson, MD

    Melanoma Cancer Track

    Malignant Melanoma:
    Multimodality Strategies that Improve Clinical Outcomes
    F. Steven Hodi Jr., MD

    Panel Discussion
    All Faculty

    Gynecologic Oncology Track

    Lecture Title To Be Determined
    Ursula A. Matulonis, MD

    Gastrointestinal Cancer Track

    Creating a New Standard for Esophageal, Gastric, and Pancreatic Cancers
    Peter C. Enzinger, MD

    Familial Gastrointestinal Cancers:
    Current Guidelines for Screening, Diagnosis, and Management
    Sapna Syngal, MD, MPH

    Leveraging Genomic and Epidemiologic Findings Toward Reducing Colorectal Cancer Risk and Mortality
    Charles S. Fuchs, MD, MPH

    Colorectal Cancer:
    The Status of Systemic Treatment for Adjuvant and Metastatic Disease Settings
    Robert J. Mayer, MD

    Panel Discussion
    All Faculty

    Hematologic Malignancies Track

    Making Sense of the Myriad Treatment Options for Non-Hodgkin and Hodgkin Lymphoma
    Arnold S. Freedman, MD

    New and Emerging Therapies in Myeloid Malignancies:
    Current Practice Paradigms
    Daniel J. DeAngelo, MD, PhD

    Myeloproliferative Neoplasms:
    Natural History, Genetic Risk Factors, Advances in Treatment
    Ayalew Tefferi, MD

    Multiple Myeloma:
    Emerging Diagnostic and Therapeutic Paradigms
    Kenneth C. Anderson, MD

    Chronic Lymphocytic Leukemia:
    Current Best Management in the Era of Targeted Therapy
    John C. Byrd, MD

    Panel Discussion
    All Faculty

    Course Goal and Overview

    The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and overall management of a wide range of common cancers.

    This innovative, live two-day curriculum provides a comprehensive update of oncologic practice, including current best practices and updated guidelines, emerging clinical evidence, and recent expert opinion in nearly all major areas of practice. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the acknowledged master clinicians of DFCI.

    Target Audience

    This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.

    Maintenance of Certification (MOC) Session***

    *** Please sign up when registering for the course to participate in our optional MOC session.

    Optional Maintenance of Certification (MOC Part II) Session 2016 Updates in Oncology

    Harold J. Burstein, MD, PhD
    Daniel J. DeAngelo, MD, PhD
    Robert J. Mayer, MD

  • Acknowledgments

    Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity.

    Amgen Boehringer Ingelheim Bristol-Myers Squibb
    Celegene Eisai Eli Lilly
    Genentech Genomic Health Merck
    Millennium Novartis Otsuka
    Pharmacyclics Taiho Oncology